- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04834414
Afkølede blodpladeundersøgelse "CHIPS" (CHIPS)
Undersøgelse af afkølede blodplader
A phase 3 randomized partial blind storage duration ranging study in patients undergoing complex cardiac surgery that will compare the transfusion of cold stored platelets to standard room temperature stored platelets. The primary objective is to establish that cold stored platelets have a non-inferiority (or superiority) to room temperature platelets.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
Western Australia
-
Murdoch, Western Australia, Australien, 6150
- Fiona Stanley Hospital
-
Nedlands, Western Australia, Australien, 6009
- Sir Charles Gairdner Hospital
-
-
-
-
Arizona
-
Pheonix, Arizona, Forenede Stater, 85054
- Mayo Clinic Arizona
-
Tuscon, Arizona, Forenede Stater, 85713
- Banner University Medical Center
-
-
California
-
Los Angeles, California, Forenede Stater, 90095
- Ronald Reagan UCLA Medical Center
-
-
Florida
-
Gainesville, Florida, Forenede Stater, 32608
- University of Florida
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Northwestern Memorial Hospital
-
Maywood, Illinois, Forenede Stater, 60153
- Loyola Universtiy Medical Center
-
-
Kansas
-
Kansas City, Kansas, Forenede Stater, 66103
- University of Kansas Medical Center
-
-
Kentucky
-
Lexington, Kentucky, Forenede Stater, 40536
- University of Kentucky
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21287
- John Hopkins
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- University of Michigan
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55455
- University of Minnesota
-
Rochester, Minnesota, Forenede Stater, 55905
- Mayo Clinic
-
-
North Carolina
-
Winston-Salem, North Carolina, Forenede Stater, 27157
- Wake Forest
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45229
- Cincinnati Children's Hospital
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97239
- Oregon Health and Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, Forenede Stater, 15232
- University of Pittsburgh Medical Center
-
-
Rhode Island
-
Providence, Rhode Island, Forenede Stater, 02910
- Rhode Island Hospital
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75235
- University of Texas Children's Medical Center
-
Dallas, Texas, Forenede Stater, 75235
- University of Texas Medical Center Clements
-
Houston, Texas, Forenede Stater, 77030
- Memorial Hermann Texas Medical Center
-
Houston, Texas, Forenede Stater, 77030
- Baylor Texas Children's
-
-
Wisconsin
-
Madison, Wisconsin, Forenede Stater, 53792
- University of Wisconsin- Madison
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- Children's Hospital of Wisconsin
-
Milwaukee, Wisconsin, Forenede Stater, 53215
- Aurora St. Luke's Medical Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Viable neonates ≥ 3 kg at time of enrollment (as defined in Section 4.1) OR age greater than 28 days and less than 85 years of age at time of consent; AND
- Planned complex cardiac surgery with planned use of cardiopulmonary bypass, with an expectation of bleeding requiring platelet transfusion.
Exclusion Criteria:
- Expected order for washed or volume reduced platelets
- Patient with known anti-platelet antibodies
- Platelet transfusion refractoriness due to anti-HLA antibodies
- Known or suspected pregnancy
- Previously randomized in this study
- Conscious objection or unwillingness to receive blood products
- Known IgA deficiency
- Known congenital platelet disorder
- Known congenital bleeding disorder
- Planned post-operative extracorporeal membrane oxygenation (ECMO), ventricular assist device (VAD), and/or continuous renal replacement therapy (CRRT)/ hemodialysis
- Patients intended to receive whole blood either intra-operative or post-operative for bleeding
- Platelet transfusion (of any type) within 24 hours prior to the date of surgery
- Pre-operative thrombocytopenia, defined as platelet count <75x10(9)/L, based on the most recent labs completed within 72 hours prior to the date of surgery.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Room Temperature Platelets
Platelets stored at 20-24 degrees Celsius |
Platelets stored at 20-24 degrees Celsius |
|
Eksperimentel: Cold Stored Platelets
Platelets stored at 1-6 degree Celsius |
Platelets stored at 1-6 degree Celsius |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Hemostatic Efficacy
Tidsramme: 24 hours after first study platelet transfusion
|
Assessed by a bleeding score, a modified Peri-Operative bleeding score: the score ranges from 1-5. A lower score signifies a better outcome. |
24 hours after first study platelet transfusion
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Chest Tube Output Through 24 Hours
Tidsramme: 24 hours from first study platelet transfusion or ICU admit (determined from which occurs last)
|
Chest tube output will be assessed by volume |
24 hours from first study platelet transfusion or ICU admit (determined from which occurs last)
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Blood Product Administration
Tidsramme: 24 and 72 hours from start time of first study platelet transfusion
|
The quantity of RBCs, Plasma, Platelets, Cryoprecipitate, and Whole blood |
24 and 72 hours from start time of first study platelet transfusion
|
|
Transfusion Associated Adverse Events
Tidsramme: within 7 days of first study platelet transfusion
|
As per CDC guidelines for transfusion associated adverse events |
within 7 days of first study platelet transfusion
|
|
Arterial Thrombotic Event
Tidsramme: within 7 days of first study platelet transfusion
|
Stroke, MI, aortic thromboic even |
within 7 days of first study platelet transfusion
|
|
Venous Thrombotic Event
Tidsramme: within 7 days of first study platelet transfusion
|
Deep vein thrombosis or pulmonary embolism confirmed by ultrasound, venography, perfusion scan, spiral CT, MRI, or pulmonary angiogram |
within 7 days of first study platelet transfusion
|
|
All Cause Mortality
Tidsramme: up to 28 days
|
Death for any reason |
up to 28 days
|
|
Total Dose of Individual Hemostatic Adjuncts (Units/kg)
Tidsramme: 24 and 72 hours from start time of first study platelet transfusion
|
Antifibrinolytic and coagulation factor concentrates |
24 and 72 hours from start time of first study platelet transfusion
|
|
Total Dose of Individual Hemostatic Adjuncts (mcg/kg)
Tidsramme: 24 and 72 hours from start time of first study platelet transfusion
|
Antifibrinolytic and coagulation factor concentrates |
24 and 72 hours from start time of first study platelet transfusion
|
|
Total Dose of Individual Hemostatic Adjuncts (mg/kg)
Tidsramme: 24 and 72 hours from start time of first study platelet transfusion
|
Antifibrinolytic and coagulation factor concentrates |
24 and 72 hours from start time of first study platelet transfusion
|
|
Total Dose of Individual Hemostatic Adjuncts (Grams/kg)
Tidsramme: 24 and 72 hours from start time of first study platelet transfusion
|
Antifibrinolytic and coagulation factor concentrates Epsilon-amino-caproic acid |
24 and 72 hours from start time of first study platelet transfusion
|
|
Mechanical Ventilation
Tidsramme: up to 28 days after first study platelet transfusion
|
Number of participants with need for mechanical ventilation |
up to 28 days after first study platelet transfusion
|
|
Length of Stay
Tidsramme: up to 28 days
|
ICU and hospital length of stay |
up to 28 days
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours - Hemoglobin
Tidsramme: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement) |
6 and 24 hours after first study platelet transfusion
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours - Hematocrit
Tidsramme: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement). |
6 and 24 hours after first study platelet transfusion
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours- Platelet Count
Tidsramme: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement) |
6 and 24 hours after first study platelet transfusion
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours- INR
Tidsramme: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement) |
6 and 24 hours after first study platelet transfusion
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours- PTT
Tidsramme: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement) |
6 and 24 hours after first study platelet transfusion
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours- Fibrinogen
Tidsramme: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement) |
6 and 24 hours after first study platelet transfusion
|
|
Unplanned Sternal Closure Delay
Tidsramme: prior to ICU admission
|
Sternum left open after cardiac surgery |
prior to ICU admission
|
|
Re-exploration for Bleeding
Tidsramme: 24 hours first study platelet transfusion
|
Return to OR after ICU admission |
24 hours first study platelet transfusion
|
|
Unplanned Extracorporeal Support Post Operatively
Tidsramme: within 48 hours of first study platelet transfusion
|
Unplanned placement on ECMO post operatively within 48 hours of 1st transfusion |
within 48 hours of first study platelet transfusion
|
|
Morbidities After ICU Admission
Tidsramme: within 7 days of first study platelet transfusion
|
Acute respiratory distress syndrome, need for and duration of renal support, renal failure, septic shock |
within 7 days of first study platelet transfusion
|
|
Measures of End Organ Injury- BUN and Creatinine
Tidsramme: within 48 hours of first study platelet transfusion worst value
|
If BUN, creatinine are collected clinically.- worst value |
within 48 hours of first study platelet transfusion worst value
|
|
Measures of End Organ Injury- Lactate
Tidsramme: within 48 hours of first study platelet transfusion worst value
|
If lactate was collected clinically. Worst value |
within 48 hours of first study platelet transfusion worst value
|
|
Measures of End Organ Injury- Troponin
Tidsramme: within 48 hours of first study platelet transfusion.
|
If lactate was collected clinically. Worst value |
within 48 hours of first study platelet transfusion.
|
|
Measures of End Organ Injury- ALT and AST
Tidsramme: within 48 hours of first study platelet transfusion.
|
If lactate was collected clinically. Worst value |
within 48 hours of first study platelet transfusion.
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Studieleder: Philip C Spinella, MD, University of Pittsburgh
- Studieleder: Marie E Steiner, MD, University of Minnesota
- Studieleder: Nicole D Zantek, MD, University of Minnesota
Publikationer og nyttige links
Generelle publikationer
- Krachey E, Viele K, Spinella PC, Steiner ME, Zantek ND, Lewis RJ. The design of an adaptive clinical trial to evaluate the efficacy of platelets stored at low temperature in surgical patients. J Trauma Acute Care Surg. 2018 Jun;84(6S Suppl 1):S41-S46. doi: 10.1097/TA.0000000000001876.
- Strandenes G, Sivertsen J, Bjerkvig CK, Fosse TK, Cap AP, Del Junco DJ, Kristoffersen EK, Haaverstad R, Kvalheim V, Braathen H, Lunde THF, Hervig T, Hufthammer KO, Spinella PC, Apelseth TO. A Pilot Trial of Platelets Stored Cold versus at Room Temperature for Complex Cardiothoracic Surgery. Anesthesiology. 2020 Dec 1;133(6):1173-1183. doi: 10.1097/ALN.0000000000003550.
- Zantek ND, Steiner ME, VanBuren JM, Lewis RJ, Berry NS, Viele K, Krachey E, Dean JM, Nelson S, Spinella PC. Design and logistical considerations for the randomized adaptive non-inferiority storage-duration-ranging CHIlled Platelet Study. Clin Trials. 2023 Feb;20(1):36-46. doi: 10.1177/17407745221126423. Epub 2022 Dec 21.
- Spinella PC, Zantek ND, VanBuren JM, Nicolson SC, Khanna AK, Klompas AM, Boisen ML, Williams TM, Monteleone M, Bashir DA, Pavey W, Smith BB, Ahmed MI, Niebler RA, Jeng E, Flynn BC, Joshi RV, Preuss JF, Goswami D, Yamada C, Lewis C, Cohn CS, Tint H, Kwak J, Sodha N, Simon ER, Van PY, Greilich PE, Booth FVM, Carter CP, Keegan A, Cap AP, Matuk J, McGlothlin A, Berry NS, Lewis RJ, Steiner ME; CHIPS Investigator Group. Cold and Room-Temperature Platelets in Cardiac Surgery: The CHIPS Randomized Clinical Trial. JAMA. 2026 Aug 17. doi: 10.1001/jama.2026.13328. Online ahead of print.
- Lewis AR, Peffley N, Klompas AM, Ashrani AA. Role of individual factor X concentrate pharmacokinetic studies in perioperative management of AL amyloidosis-associated acquired factor X deficiency. Transfusion. 2023 Sep;63(9):1773-1777. doi: 10.1111/trf.17477. Epub 2023 Jul 10.
- Klompas AM, Stubbs J. Massive transfusion protocol: What's in a name? Transfusion. 2023 Apr;63(4):896-897. doi: 10.1111/trf.17297. No abstract available.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CHIPS
- W81XWH2090021 (Andet bevillings-/finansieringsnummer: DoD)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .